Zahnow C A, Cardiff R D, Laucirica R, Medina D, Rosen J M
Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Cancer Res. 2001 Jan 1;61(1):261-9.
The transcription factor, CCAAT/enhancer binding protein beta (C/EBPbeta), regulates the expression of genes involved in proliferation and terminal differentiation. Dimerization of the dominant-negative C/EBPbeta-liver-enriched inhibitory protein (LIP) isoform with the C/EBPbeta-liver-enriched activating protein (LAP) isoform inhibits the transcriptional activation of genes involved in differentiation. Consequently, an increase in LIP levels may inhibit terminal differentiation and lead to proliferation. C/EBPbeta-LIP and LAP are crucial for mammary gland development (G. W. Robinson et al., Genes Dev., 12: 1907-1916, 1998; T. N. Seagroves et al., Genes Dev., 12: 1917-1928, 1998) and are also overexpressed in breast cancer (B. Raught et al., Cancer Res., 56: 4382-4386. 1996; C. A. Zahnow et al., J. Natl. Cancer Inst., 89: 1887-1891, 1997); however, little is known about how these isoforms differentially regulate cell cycle progression. To address this question, C/EBPbeta-LIP was overexpressed in both the mammary glands of transgenic mice and in cultured TM3 mammary epithelial cells. Here we report that the involuted mammary glands from transgenic mice overexpressing C/EBPbeta-LIP contain both focal and diffuse alveolar hyperplasia and, less frequently, contain mammary intraepithelial neoplasias (high grade) and invasive and noninvasive carcinomas. Likewise, cultured TM3 cells, stably expressing C/EBPbeta-LIP, showed an increase in proliferation and foci formation attributable to a reentry into S-phase during cellular confluence. These results demonstrate that C/EBPbeta-LIP can induce epithelial proliferation and the formation of mammary hyperplasias and suggest that a C/EBPbeta-LIP-initiated growth cascade may be susceptible to additional oncogenic hits, which could result in the initiation and progression of neoplasia.
转录因子CCAAT/增强子结合蛋白β(C/EBPβ)可调节参与细胞增殖和终末分化的基因的表达。显性负性C/EBPβ-肝脏富集抑制蛋白(LIP)亚型与C/EBPβ-肝脏富集激活蛋白(LAP)亚型的二聚化会抑制参与分化的基因的转录激活。因此,LIP水平的升高可能会抑制终末分化并导致细胞增殖。C/EBPβ-LIP和LAP对乳腺发育至关重要(G. W. 罗宾逊等人,《基因与发育》,12: 1907 - 1916,1998;T. N. 西格罗夫斯等人,《基因与发育》,12: 1917 - 1928,1998),在乳腺癌中也过表达(B. 劳特等人,《癌症研究》,56: 4382 - 4386,1996;C. A. 扎诺等人,《美国国家癌症研究所杂志》,89: 1887 - 1891,1997);然而,关于这些亚型如何差异调节细胞周期进程却知之甚少。为了解决这个问题,C/EBPβ-LIP在转基因小鼠的乳腺以及培养的TM3乳腺上皮细胞中均过表达。在此我们报告,过表达C/EBPβ-LIP的转基因小鼠的退化乳腺中既有局灶性和弥漫性肺泡增生,较少见的还有乳腺上皮内瘤变(高级别)以及浸润性和非浸润性癌。同样,稳定表达C/EBPβ-LIP的培养TM3细胞在细胞汇合期间重新进入S期,导致增殖和灶状形成增加。这些结果表明,C/EBPβ-LIP可诱导上皮增殖和乳腺增生的形成,并提示由C/EBPβ-LIP启动的生长级联反应可能易受其他致癌因素的影响,这可能导致肿瘤的起始和进展。